Management, Outcomes, and Predictors of Mortality of Cryptococcus Infection in Patients Without HIV: A Multicenter Study in 46 Hospitals in Australia and New Zealand.

Background Limited data exist regarding outcomes of cryptococcosis in patients without human immunodeficiency virus (HIV), and few studies have compared outcomes of Cryptococcus gattii versus Cryptococcus neoformans infection. Methods We conducted a retrospective study in 46 Australian and New Zeala...

Descripción completa

Detalles Bibliográficos
Publicado en:Clinical Infectious Diseases Vol. 80; no. 4; pp. 817 - 826
Autores principales: Coussement, Julien, Heath, Christopher H, Roberts, Matthew B, Lane, Rebekah J, Spelman, Tim, Smibert, Olivia C, Longhitano, Anthony, Morrissey, C Orla, Nield, Blake, Tripathy, Monica, Davis, Joshua S, Kennedy, Karina J, Lynar, Sarah A, Crawford, Lucy C, Crawford, Simeon J, Smith, Benjamin J, Gador-Whyte, Andrew P, Haywood, Rose, Mahony, Andrew A, Howard, Julia C
Formato: research tables/charts Journal Article
Publicado: Oxford University Press / USA 4/15/2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=184862014&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 184862014
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10584838
        46X
      jtl: Clinical Infectious Diseases
      issn: 10584838
      maglogo: N
    pubinfo:
      dt: 4/15/2025
      vid: 80
      iid: 4
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        184862014
        184862014
        184862014
        10.1093/cid/ciae630
        184862014
      ppf: 817
      ppct: 9
      formats:
      tig:
        atl: Management, Outcomes, and Predictors of Mortality of Cryptococcus Infection in Patients Without HIV: A Multicenter Study in 46 Hospitals in Australia and New Zealand.
      aug:
        au:
          Coussement, Julien
          Heath, Christopher H
          Roberts, Matthew B
          Lane, Rebekah J
          Spelman, Tim
          Smibert, Olivia C
          Longhitano, Anthony
          Morrissey, C Orla
          Nield, Blake
          Tripathy, Monica
          Davis, Joshua S
          Kennedy, Karina J
          Lynar, Sarah A
          Crawford, Lucy C
          Crawford, Simeon J
          Smith, Benjamin J
          Gador-Whyte, Andrew P
          Haywood, Rose
          Mahony, Andrew A
          Howard, Julia C
        affil: Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
      sug:
        subj:
          Cryptococcosis Therapy
          Cryptococcosis Mortality
          Mortality Risk Factors
          Risk Assessment Evaluation
          Treatment Outcomes Evaluation
          Hospitals Australia
          Hospitals New Zealand
          Human
          Multicenter Studies
          Retrospective Design
          Australia
          New Zealand
          Univariate Statistics
          Cox Proportional Hazards Model
          Descriptive Statistics
          Data Analysis Software
          Confidence Intervals
          Odds Ratio
          Male
          Female
          Middle Age
          Aged
          Aged, 80 and Over
          Middle Aged: 45-64 years
          Aged: 65+ years
          Aged, 80 & over
          Male
          Female
      ab: Background Limited data exist regarding outcomes of cryptococcosis in patients without human immunodeficiency virus (HIV), and few studies have compared outcomes of Cryptococcus gattii versus Cryptococcus neoformans infection. Methods We conducted a retrospective study in 46 Australian and New Zealand hospitals to determine the outcomes of cryptococcosis in patients without HIV diagnosed between 2015 and 2019 and compared outcomes of C. gattii versus C. neoformans infections. Multivariable analysis identified predictors of mortality within 1 year. Results Of 426 patients, 1-year all-cause mortality was 21%. Cryptococcus gattii infection was associated with lower mortality than C. neoformans (adjusted odds ratio [OR], 0.47; 95% confidence interval [CI],.23–.95), while severe neurological symptoms at presentation were the strongest predictor of death (adjusted OR, 8.46; 95% CI, 2.99–23.98). Almost all (99.5%) patients with central nervous system (CNS) infection received induction antifungal therapy versus 27.7% with isolated pulmonary cryptococcosis. The most common regimen in CNS disease was liposomal amphotericin B with flucytosine (93.8%; mean duration, 31 ± 13 days). Among patients with CNS cryptococcosis, C. gattii infection was associated with higher risk of immune reconstitution inflammatory response (C-IRIS) than C. neoformans (21% versus 3%, P <.001). Nineteen patients received amphotericin B-based re-induction therapy for suspected relapse, but none had microbiological relapse. Serum cryptococcal antigen positivity and lung imaging abnormalities resolved slowly (resolution at 1 year in 25% and 34% of patients, respectively). Conclusions Compared with C. neoformans , C. gattii infection demonstrated lower mortality but higher C-IRIS risk in CNS infection. Severe neurological symptoms were the strongest predictor of mortality.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N